|
Bcom, FCMA, FCCA, FCT, CBIM
Joined the board of Amersham International plc in 1988 as a Non-executive
Director, becoming Chairman, Nycomed Amersham plc in 1999.
Recruited as Finance Director of British Aerospace plc in July 1992, becoming
Vice Chairman in April 1998. Retired from British Aerospace at the end
of September 1999. Also serves as Non-executive Chairman of Morse plc,
Avecia Ltd and a Non-executive Director of Tunstall Holdings Limited,
Oasis International Leasing in Abu Dhabi
and Orange plc. Age 57.
Siv.øk., MBA
Joined the board of Nycomed ASA in 1996 and was Chairman of Nycomed Amersham
plc from 1997 to 1999.
Was Chief Executive of Vesta Insurance Group from 1986 to 1994 and from
1994 combined his own consultancy and investment firm with several Non-executive
board positions. Also serves as Chairman of Nera plc, NHST, Co-Chairman
of Corporate Assembly SAS and is a board member of Skandia plc and Bergesen
plc. Age 52
BA, MIPM, MBIM
Joined Amersham International plc in 1990 as Managing Director of Life
Sciences, becoming Vice Chairman Nycomed Amersham plc, and Deputy Chairman
Amersham Pharmacia Biotech in 2000.
Held various senior management positions in British industry, including
roles at Calmic International, Coopers Animal Health and Wellcome Biotech.
Also serves as Chairman of KuDOS Pharmaceuticals Limited and a Non-executive
Director of Pharmagene plc. Age 54.
BA, FCA
Joined Amersham International plc in 1989 as Chief Executive.
Held various positions with the Wellcome Foundation before becoming Head
of Finance and Administration for Continental Europe, Africa and Asia
in 1976. Appointed Managing Director, Wellcome Biotech in 1980 and Commercial
Director in 1986.
Also serves as a Non-executive Director of Marconi plc and Chairman of
The Prince’s Trust. Knighted in June 2000 for services to the life
sciences industry. Age 53.
|
|
BA, ACA
Joined Amersham International plc as Group Financial Controller in 1991,
becoming Commercial Controller in 1994 and Company Secretary and Director
of Corporate Development in 1996, before being appointed to Finance Director
in 1997.
Worked for Arthur Andersen & Co from 1981, in positions including
Audit and Accounting Manager and Partner, Corporate Finance and Investigations.
Age 41.
BPharm, PhD, FRPharmS, FRSC
Joined Nycomed Amersham plc in 1999 as Chief Executive of Nycomed Amersham
Imaging.
Was Chief Executive of Chiroscience plc from 1994 to 1999 and for 15 years
prior to this held board positions in several subsidiary companies at
Glaxo. Appointed to the Biotechnology and Biological Sciences Research
Council in 1998 and also served as a Director of The BioIndustry Association
and was appointed to the Board of Intrabiotics Pharmaceuticals Inc in
1998. Age 54
BSc
Joined Nycomed Amersham plc in 2000 as Group Human Resources Director.
Previously with Laporte plc for four years as Group Human Resources Director.
Joined Laporte from Fisons plc where he was Group Human Resources Director
from 1985 to 1996.
Earlier career included sales and marketing , consulting and human resources
appointments in companies including International Computers Limited and
Air Products & Chemicals Inc. Age 54.
MB BCh, FRCP, FRCPath, FRS
Joined the board of Nycomed Amersham plc in 2000. Has been Regius Professor
of Physic at the University of Cambridge since 1987; is Honorary Consultant
Physician at Addenbrooke’s NHS Trust; member of Council of the Royal
Society; Chairman of the British Heart Foundation; member of Council of
Heads of Medical Schools and Deans of UK Faculties Medicine; Governor,
PPP Healthcare Medical Trust: Governing Trustee, The Nuffield Trust; Trustee,
Strangeways Research Laboratory; member of Scientific Advisory Boards
of the Gairdner Foundation and Merck Institute. Age 63.
OBE, BSc
Joined the board of Amersham International plc in 1997.Joined AXA Group
in 1997 after a 20 year career with the Barclays Group. Is currently Senior
Executive Vice President and a member of the AXA Group Executive Committee,
Chairman and Chief Executive of AXA Investment Managers. Also serves as
a Director of Allied Domecq and President of the European Asset Management
Association. Age 55.
|
|
MSc
Joined the board of Hafslund Nycomed ASA in 1994 as an elected employee.
Began career as a Research Scientist, peptide chemistry in 1980, holding
management positions in chemistry research and development and from 1991
has been a Senior Research Scientist in Nycomed Amersham Imaging. Age
54.
MBA
Joined the board of Hafslund Nycomed ASA in 1994.
From 1966 to 1989 was employed by the Sandoz Group, rising from Management
Trainee to President and Chief Executive. Became President and Chief Executive
of Sterling Winthrop Inc in 1994 and in 1998 was appointed Chief Executive
of NMT Management AG. Age 61.
MD
Joined the board of Nycomed ASA in 1997.
Has held a number of positions in medical institutions, societies and
committees and in 1983 was appointed Professor of Medicine at the University
of Oslo. He is Head of Institute of Immunology at The National Hospital
and University of Oslo. Also serves as Chairman to the Committee for Xenotransplantation
and Chairman of the Research Council at The National Hospital. Age 62.
FRCP
Joined the board of Nycomed Amersham plc in 2001.
Has had a long career with ICI Pharmaceuticals and was appointed Vice
President for Clinical Research and Medical Affairs in the USA in 1988.
In 1990 joined its board as Medical Director. Was appointed Executive
Vice President Product Strategy and Licensing for AstraZeneca in 1999
and currently serves as Chair on its Portfolio Management and Licensing
Executive Sub Committees. Also serves as a Director of the British Pharmaceuticals
Group and has been Vice President of ABPI since 1998. Age 53.
 |
